Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Non-cash Items (2016 - 2025)

Ocular Therapeutix has reported Non-cash Items over the past 12 years, most recently at $10.9 million for Q4 2025.

  • For Q4 2025, Non-cash Items fell 73.89% year-over-year to $10.9 million; the TTM value through Dec 2025 reached $10.9 million, down 73.89%, while the annual FY2025 figure was $10.9 million, 4.97% down from the prior year.
  • Non-cash Items for Q4 2025 was $10.9 million at Ocular Therapeutix, down from $41.6 million in the prior quarter.
  • Over five years, Non-cash Items peaked at $41.6 million in Q4 2024 and troughed at $7000.0 in Q4 2022.
  • A 5-year average of $13.8 million and a median of $10.9 million in 2025 define the central range for Non-cash Items.
  • Biggest five-year swings in Non-cash Items: crashed 99.95% in 2022 and later surged 47957.14% in 2023.
  • Year by year, Non-cash Items stood at $13.3 million in 2021, then crashed by 99.95% to $7000.0 in 2022, then surged by 47957.14% to $3.4 million in 2023, then skyrocketed by 1135.73% to $41.6 million in 2024, then tumbled by 73.89% to $10.9 million in 2025.
  • Business Quant data shows Non-cash Items for OCUL at $10.9 million in Q4 2025, $41.6 million in Q4 2024, and $3.4 million in Q4 2023.